Non Clinical Model to Assess the Mechanism of Action of a Combined Hyaluronic Acid, Chondroitin Sulfate and Calcium Chloride: HA+CS+CaCl₂ Solution on a 3D Human Reconstructed Bladder Epithelium

References

• Klein RD, Hultgren SJ. Urinary tract infections: microbial pathogenesis, host-pathogen interactions and new treatment strategies. Nat Rev Microbiol. 2020;18(4):211–226. doi:10.1038/s41579-020-0324-0
   PubMed Web of Science ®Google Scholar
• Foxman B, Brown P. Epidemiology of urinary tract infections: transmission and risk factors, incidence, and costs. Infect Dis Clin North Am. 2003;17(2):227–241. doi:10.1016/s0891-5520(03)00005-9
   PubMed Web of Science ®Google Scholar
• Hunstad DA, Justice SS, Hung CS, Lauer SR, Hultgren SJ. Suppression of bladder epithelial cytokine responses by uropathogenic Escherichia coli. Infect Immun. 2005;73(7):3999–4006. doi:10.1128/IAI.73.7.3999-4006.2005
   PubMed Web of Science ®Google Scholar
• Billips BK, Forrestal SG, Rycyk MT, Johnson JR, Klumpp DJ, Schaeffer AJ. Modulation of host innate immune response in the bladder by uropathogenic Escherichia coli. Infect Immun. 2007;75(11):5353–5360. doi:10.1128/IAI.00922-07
   PubMed Web of Science ®Google Scholar
• Billips BK, Schaeffer AJ, Klumpp DJ. Molecular basis of uropathogenic Escherichia coli evasion of the innate immune response in the bladder. Infect Immun. 2008;76(9):3891–3900. doi:10.1128/IAI.00069-08
   PubMed Web of Science ®Google Scholar
• Kaper JB, Nataro JP, Mobley HL. Pathogenic Escherichia coli. Nat Rev Microbiol. 2004;2(2):123–140. doi:10.1038/nrmicro818
   PubMed Web of Science ®Google Scholar
• Kudinha T The Pathogenesis of Escherichia coli Urinary Tract Infection [Internet]. Escherichia coli - Recent Advances on Physiology, Pathogenesis and Biotechnological Applications. InTech; 2017.
   Google Scholar
• Mobley HL, Island MD, Massad G. Virulence determinants of uropathogenic Escherichia coli and Proteus mirabilis. Kidney Int Suppl. 1994;47:S129–S136.
   PubMedGoogle Scholar
• Schilling JD, Lorenz RG, Hultgren SJ. Effect of trimethoprim-sulfamethoxazole on recurrent bacteriuria and bacterial persistence in mice infected with uropathogenic Escherichia coli. Infect Immun. 2002;70(12):7042–7049. doi:10.1128/IAI.70.12.7042-7049.2002
   PubMed Web of Science ®Google Scholar
• Rosen DA, Hooton TM, Stamm WE, Humphrey PA, Hultgren SJ. Detection of intracellular bacterial communities in human urinary tract infection. PLoS Med. 2007;4(12):e329. doi:10.1371/journal.pmed.0040329
   PubMed Web of Science ®Google Scholar
• Mulvey MA, Schilling JD, Hultgren SJ. Establishment of a persistent Escherichia coli reservoir during the acute phase of a bladder infection. Infect Immun. 2001;69(7):4572–4579. doi:10.1128/IAI.69.7.4572-4579.2001
   PubMed Web of Science ®Google Scholar
• Stærk K, Khandige S, Kolmos HJ, Møller-Jensen J, Andersen TE. Uropathogenic Escherichia coli express type 1 fimbriae only in surface adherent populations under physiological growth conditions. J Infect Dis. 2016;213(3):386–394. doi:10.1093/infdis/jiv422
   PubMed Web of Science ®Google Scholar
• Gupta K, Grigoryan L, Trautner B. Urinary tract infection. Ann Intern Med. 2017;167(7):ITC49–ITC64. doi:10.7326/AITC201710030
   PubMed Web of Science ®Google Scholar
• EAU Guidelines on Urological Infections. presented at the EAU annual congress Milan, Italy 2023; 2023.
   Google Scholar
• Anger JT, Bixler BR, Holmes RS, Lee UJ, Santiago-Lastra Y, Selph SS. Updates to recurrent uncomplicated urinary tract infections in women: AUA/CUA/SUFU guideline. J Urol. 2022;208(3):536–541. doi:10.1097/JU.0000000000002860
   PubMed Web of Science ®Google Scholar
• Damiano R, Quarto G, Bava I, et al. Prevention of recurrent urinary tract infections by intravesical administration of hyaluronic acid and chondroitin sulphate: a placebo-controlled randomised trial [published correction appears in Eur Urol. 2011 Jul;60(1):193]. Eur Urol. 2011;59(4):645–651. doi:10.1016/j.eururo.2010.12.039
   PubMed Web of Science ®Google Scholar
• De Vita D, Giordano S. Effectiveness of intravesical hyaluronic acid/chondroitin sulfate in recurrent bacterial cystitis: a randomized study. Int Urogynecol J. 2012;23(12):1707–1713. doi:10.1007/s00192-012-1794-z
   PubMed Web of Science ®Google Scholar
• Goddard JC, Janssen DAW. Intravesical hyaluronic acid and chondroitin sulfate for recurrent urinary tract infections: systematic review and meta-analysis. Int Urogynecol J. 2018;29(7):933–942. doi:10.1007/s00192-017-3508-z
   PubMed Web of Science ®Google Scholar
• Wiles TJ, Kulesus RR, Mulvey MA. Origins and virulence mechanisms of uropathogenic Escherichia coli. Exp Mol Pathol. 2008;85(1):11–19. doi:10.1016/j.yexmp.2008.03.007
   PubMed Web of Science ®Google Scholar
• Hilbert DW, Pascal KE, Libby EK, Mordechai E, Adelson ME, Trama JP. Uropathogenic Escherichia coli dominantly suppress the innate immune response of bladder epithelial cells by a lipopolysaccharide- and Toll-like receptor 4-independent pathway. Microbes Infect. 2008;10(2):114–121. doi:10.1016/j.micinf.2007.10.012
   PubMed Web of Science ®Google Scholar
• Maldonado-Barragán A, Mshana SE, Keenan K, et al. Predominance of multidrug-resistant (MDR) bacteria causing urinary tract infections (UTIs) among symptomatic patients in East Africa: a call for action. medRxiv. 2023. doi:10.1101/2023.06.13.23291274
   PubMedGoogle Scholar
• Penn R, Ward BJ, Strande L, Maurer M. Review of synthetic human faeces and faecal sludge for sanitation and wastewater research. Water Res. 2018;132:222–240.
   PubMed Web of Science ®Google Scholar
• Casiraghi A, Ranzini F, Musazzi UM, Franzè S, Meloni M, Minghetti P. In vitro method to evaluate the barrier properties of medical devices for cutaneous use. Regul Toxicol Pharmacol. 2017;90:42–50. doi:10.1016/j.yrtph.2017.08.007
   PubMed Web of Science ®Google Scholar
• Gordon S, Daneshian M, Bouwstra J, et al. Non-animal models of epithelial barriers (skin, intestine and lung) in research, industrial applications and regulatory toxicology. ALTEX. 2015;32(4):327–378. doi:10.14573/altex.1510051
   PubMedGoogle Scholar
• Ayehunie S, Wang YY, Landry T, Bogojevic S, Cone RA. Hyperosmolal vaginal lubricants markedly reduce epithelial barrier properties in a three-dimensional vaginal epithelium model [published correction appears in Toxicol Rep. 2020 Dec 25;8:62–63]. Toxicol Rep. 2017;(5):134–140. doi:10.1016/j.toxrep.2017.12.011
   PubMedGoogle Scholar
• De Jong WH, Hoffmann S, Lee M, et al. Round robin study to evaluate the reconstructed human epidermis (RhE) model as an in vitro skin irritation test for detection of irritant activity in medical device extracts. Toxicol In Vitro. 2018;50:439–449. doi:10.1016/j.tiv.2018.01.001
   PubMed Web of Science ®Google Scholar
• Meloni M, Balzaretti S, Ceriotti L. Medical devices biocompatibility assessment on HCE: evidences of delayed cytotoxicity of preserved compared to preservative free eye drops. Regul Toxicol Pharmacol. 2019;106:81–89. doi:10.1016/j.yrtph.2019.04.022
   PubMed Web of Science ®Google Scholar
• Sica VP, Friberg MA, Teufel AG, et al. Safety assessment scheme for menstrual cups and application for the evaluation of a menstrual cup comprised of medical grade silicone. EBioMedicine. 2022;86:104339. doi:10.1016/j.ebiom.2022.104339
   PubMed Web of Science ®Google Scholar
• Cárdenas-Calderón C, Veloso-Giménez V, González T, et al. Development of an implantable three-dimensional model of a functional pathogenic multispecies biofilm to study infected wounds. Sci Rep. 2022;12(1):21846. doi:10.1038/s41598-022-25569-5
   PubMed Web of Science ®Google Scholar
• De Servi B, Ranzini F. Protective efficacy of antidiarrheal agents in a permeability model of Escherichia coli-infected CacoGoblet® cells. Future Microbiol. 2017;12:1449–1455. doi:10.2217/fmb-2016-0195
   PubMed Web of Science ®Google Scholar